Many women with fatty liver disease wonder whether pregnancy is safe for them and their baby. Fatty liver disease, or hepatic steatosis, is increasingly common in the UK, affecting approximately one in three adults. For most women with uncomplicated fatty liver disease, pregnancy is generally considered safe with appropriate medical supervision. However, the answer depends on several factors, including the severity of liver disease, degree of scarring (fibrosis), overall liver function, and the presence of associated conditions such as obesity or diabetes. Understanding your specific situation and working closely with healthcare professionals ensures the best outcomes for both mother and baby.
Summary: For most women with uncomplicated fatty liver disease (simple steatosis), pregnancy is generally safe with appropriate medical supervision and monitoring.
- Fatty liver disease severity determines pregnancy safety—simple steatosis is usually compatible with pregnancy, whilst advanced fibrosis or cirrhosis requires specialist hepatology assessment before conception.
- Pre-existing fatty liver disease does not increase the risk of acute fatty liver of pregnancy (AFLP), which is a separate, rare obstetric emergency.
- Women with fatty liver disease have increased risks of gestational diabetes and pre-eclampsia, often related to associated metabolic conditions rather than the liver disease itself.
- Preconception assessment should include liver function tests, fibrosis scoring (FIB-4 or NAFLD fibrosis score), and optimisation of associated conditions such as diabetes and hypertension.
- Management during pregnancy focuses on regular monitoring, lifestyle modifications (balanced diet and physical activity), and screening for gestational diabetes and pre-eclampsia.
- Women should seek urgent medical advice for symptoms including jaundice, severe abdominal pain, persistent vomiting, severe itching, or signs of pre-eclampsia during pregnancy.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding Fatty Liver Disease and Pregnancy
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. This condition exists in two main forms: non-alcoholic fatty liver disease (NAFLD) – increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) – which affects individuals who drink little or no alcohol, and alcohol-related liver disease (ARLD), related to excessive alcohol consumption. NAFLD/MASLD is increasingly common in the UK, affecting approximately one in three adults, often associated with obesity, type 2 diabetes, and metabolic syndrome.
When considering pregnancy, it is essential to distinguish between pre-existing fatty liver disease and a rare but serious pregnancy-specific condition called acute fatty liver of pregnancy (AFLP). Pre-existing NAFLD typically represents a chronic, stable condition that many women have before conception, whilst AFLP is an obstetric emergency that develops during the third trimester or immediately postpartum. The two conditions are entirely separate entities with different causes, presentations, and management approaches.
The liver plays a vital role during pregnancy, processing increased metabolic demands and hormonal changes. In healthy pregnancies, the liver adapts to these physiological changes without difficulty. For women with pre-existing fatty liver disease, understanding how this condition may interact with pregnancy is crucial for planning and ensuring optimal maternal and foetal outcomes. Most women with uncomplicated NAFLD can have successful pregnancies with appropriate medical supervision.
The severity of fatty liver disease varies considerably along a continuum. Simple steatosis (fat accumulation alone) is generally benign, whilst non-alcoholic steatohepatitis (NASH) involves inflammation and liver cell damage. Over time, NASH may progress to fibrosis (scarring) and, in some cases, cirrhosis (advanced scarring with impaired liver function). Women planning pregnancy should understand their specific diagnosis, degree of fibrosis, and liver function status, as disease severity significantly influences pregnancy planning, risk, and management strategies.
Is It Safe to Get Pregnant with Fatty Liver?
For most women with uncomplicated fatty liver disease, pregnancy is generally considered safe. Simple hepatic steatosis without significant inflammation or fibrosis does not typically contraindicate pregnancy. Many women with NAFLD successfully carry pregnancies to term without major complications. However, the safety of pregnancy depends significantly on the severity of liver disease, degree of fibrosis, overall liver function, and the presence of associated metabolic conditions.
Women with well-compensated liver disease and normal liver function tests can usually proceed with pregnancy planning after appropriate medical assessment. The key consideration is whether the liver can meet the increased metabolic demands of pregnancy. In cases of simple steatosis with preserved liver function, the liver typically adapts adequately to pregnancy-related physiological changes, including increased blood volume, altered hormone levels, and enhanced metabolic activity.
However, certain circumstances require more cautious consideration and specialist input. Women with advanced liver fibrosis, cirrhosis, or significantly impaired liver function face higher risks during pregnancy. These conditions may compromise the liver's ability to handle pregnancy-related demands and increase the risk of maternal complications, including portal hypertension, variceal bleeding, and hepatic decompensation. In such cases, pregnancy should be carefully planned in consultation with hepatology and obstetric specialists. Women with suspected or confirmed advanced liver disease should undergo preconception hepatology review, including assessment for varices (enlarged veins that may bleed) and optimisation of liver health. Effective contraception is advised until the woman has been fully assessed and any necessary treatment completed.
The presence of associated conditions such as obesity, type 2 diabetes, hypertension, or polycystic ovary syndrome (PCOS) – all commonly linked with NAFLD – may influence pregnancy safety more than the fatty liver itself. These metabolic conditions can increase risks of gestational diabetes, pre-eclampsia, and other pregnancy complications. Therefore, a comprehensive assessment of overall health, rather than fatty liver status alone, determines pregnancy safety. Women should discuss their individual circumstances with healthcare professionals to receive personalised advice based on their specific medical profile.
Risks and Complications During Pregnancy
Women with pre-existing fatty liver disease may face certain increased risks during pregnancy, though many of these relate to associated metabolic conditions rather than the fatty liver itself. Gestational diabetes occurs more frequently in women with NAFLD. Research suggests that women with NAFLD have an increased risk of developing gestational diabetes compared to those without fatty liver disease, though absolute risks remain modest. This complication requires careful monitoring and management to prevent adverse outcomes for both mother and baby.
Pre-eclampsia, a serious condition characterised by high blood pressure and protein in the urine, also appears more common in women with metabolic syndrome and NAFLD. The shared pathophysiological mechanisms involving endothelial dysfunction, insulin resistance, and inflammation may explain this association. Pre-eclampsia can lead to serious maternal and foetal complications if not promptly recognised and managed, including premature delivery, placental abruption, and in severe cases, eclamptic seizures or HELLP syndrome (haemolysis, elevated liver enzymes, and low platelets). Women at increased risk of pre-eclampsia may be offered low-dose aspirin (75–150 mg daily) from 12 weeks of pregnancy as a preventive measure, in line with NICE guidance.
There is some evidence suggesting modestly increased risks of preterm birth and caesarean delivery in women with NAFLD, though the absolute risk remains relatively low. These associations may reflect the complexity of managing multiple metabolic conditions during pregnancy rather than direct effects of hepatic steatosis. Additionally, babies born to mothers with NAFLD may have marginally higher birth weights or be large for gestational age, potentially related to maternal metabolic dysfunction and gestational diabetes.
It is crucial to emphasise that acute fatty liver of pregnancy (AFLP) is not more common in women with pre-existing NAFLD. There is no established link between chronic fatty liver disease and this rare obstetric emergency. AFLP is a distinct condition with different pathophysiology, typically presenting in the third trimester with symptoms including nausea, vomiting, abdominal pain, and jaundice. This condition requires immediate medical attention and delivery of the baby. Women with pre-existing fatty liver should be aware of AFLP symptoms but understand that their baseline condition does not increase their risk of developing this serious complication.
Medical Assessment Before Conception
Women with known or suspected fatty liver disease should undergo comprehensive medical assessment before attempting conception. This preconception evaluation allows healthcare professionals to assess liver function, identify potential risks, and optimise health before pregnancy. The assessment typically begins with a detailed medical history, including documentation of any previous liver investigations, associated metabolic conditions, medications, and family history of liver disease or pregnancy complications.
Liver function tests (LFTs) form the cornerstone of preconception assessment. These blood tests measure enzymes and proteins that indicate how well the liver is functioning, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), bilirubin, and albumin. Mildly elevated transaminases are common in NAFLD and do not necessarily preclude pregnancy, but significantly abnormal results warrant further investigation. Additional blood tests may include full blood count, clotting studies, glucose levels, lipid profile, and tests for viral hepatitis to exclude other causes of liver disease.
Assessment of liver fibrosis is important for risk stratification. In line with NICE guidance (NG49), initial assessment uses non-invasive scoring systems such as the FIB-4 score or NAFLD fibrosis score, calculated from routine blood tests and clinical information. If these scores suggest possible advanced fibrosis or are indeterminate, further testing with the Enhanced Liver Fibrosis (ELF) blood test is recommended. An ELF score of 10.51 or above suggests advanced fibrosis and warrants referral to a hepatologist for specialist assessment. Liver ultrasound can assess the degree of fatty infiltration and exclude other liver pathology. In specialist settings, FibroScan (transient elastography) may be used to measure liver stiffness, which correlates with fibrosis severity. These investigations help stratify risk and guide pregnancy planning, particularly identifying women who need specialist hepatology input before conception.
The preconception period also provides an opportunity to address modifiable risk factors. Healthcare professionals may recommend weight optimisation through dietary changes and increased physical activity, as even modest weight loss (5–10% of body weight) can significantly improve liver health and metabolic parameters. Management of associated conditions such as diabetes, hypertension, and dyslipidaemia should be optimised, with medication reviews to ensure any treatments are pregnancy-safe. Women taking medications for metabolic conditions often need to switch to pregnancy-compatible alternatives. For example, statins, ACE inhibitors, angiotensin receptor blockers (ARBs), SGLT2 inhibitors, and GLP-1 receptor agonists should be stopped before conception, and alternative management strategies discussed. Women should check the BNF or discuss with their GP or pharmacist regarding the safety of all medications in pregnancy.
Folic acid supplementation should be commenced at least one month before conception and continued until 12 weeks of pregnancy. Most women require 400 micrograms daily. However, women at higher risk – including those with BMI of 30 kg/m² or above, diabetes, a previous baby with a neural tube defect, or taking certain antiepileptic medicines – should take a higher dose of 5 milligrams daily. Women should also receive advice on alcohol abstinence (if relevant) and smoking cessation support if needed. This comprehensive preconception approach maximises the chances of a healthy pregnancy and positive outcomes.
Managing Fatty Liver During Pregnancy
Management of fatty liver disease during pregnancy focuses on monitoring maternal and foetal wellbeing whilst addressing associated metabolic conditions. Regular antenatal care is essential, typically involving more frequent appointments than standard pregnancy care, particularly for women with additional risk factors such as obesity, diabetes, or hypertension. Monitoring includes regular blood pressure checks, urine testing for protein, and assessment of foetal growth and wellbeing through ultrasound scans.
Liver function tests should be monitored periodically throughout pregnancy, with frequency determined by baseline liver function and presence of symptoms. It is important to recognise that normal physiological changes in pregnancy affect liver blood tests: alkaline phosphatase (ALP) typically rises (due to placental production), whilst albumin falls (due to haemodilution). Mild fluctuations in liver enzymes can occur, but significant elevations of transaminases (ALT, AST) or bilirubin, or deteriorating trends, require investigation to exclude pregnancy-specific liver conditions (such as intrahepatic cholestasis of pregnancy, pre-eclampsia, HELLP syndrome, or AFLP) or other complications. Women should be educated about symptoms that might indicate liver problems, including persistent nausea and vomiting (beyond typical morning sickness), abdominal pain, jaundice (yellowing of skin or eyes), dark urine, pale stools, or severe itching (particularly affecting palms and soles).
Screening for gestational diabetes is particularly important for women with NAFLD. In the UK, screening is risk-based rather than universal. Women with NAFLD often meet criteria for screening due to associated risk factors such as BMI of 30 kg/m² or above, previous gestational diabetes, family history of diabetes, or certain ethnic backgrounds. Screening typically involves an oral glucose tolerance test (OGTT) at 24–28 weeks gestation, though earlier testing may be recommended for high-risk women. If gestational diabetes develops, management includes dietary modifications and blood glucose monitoring. If lifestyle measures prove insufficient to control blood glucose, metformin is usually the first-line medication option; insulin therapy is added or used instead if metformin is inadequate, not tolerated, or contraindicated, in line with NICE guidance (NG3).
For women identified as being at increased risk of pre-eclampsia based on NICE criteria (NG133) – which may include those with obesity, diabetes, hypertension, or other risk factors often present alongside NAFLD – low-dose aspirin (75–150 mg daily) should be offered from 12 weeks of pregnancy until birth as a preventive measure.
Lifestyle modifications remain the cornerstone of NAFLD management during pregnancy. A balanced, nutritious diet supports both maternal liver health and foetal development. Women should focus on whole foods, including fruits, vegetables, whole grains, lean proteins, and healthy fats, whilst limiting processed foods, refined sugars, and saturated fats. However, pregnancy is not the time for weight loss diets; rather, the goal is appropriate gestational weight gain. Most women gain around 10–12.5 kg during pregnancy, though this varies based on pre-pregnancy body mass index (BMI). Women should discuss healthy weight management with their midwife or obstetrician and can access NHS resources on weight management in pregnancy.
Physical activity benefits both liver health and pregnancy outcomes. In line with UK Chief Medical Officers' guidance, unless contraindicated, pregnant women should aim for at least 150 minutes of moderate-intensity activity weekly, such as brisk walking, swimming, or pregnancy-specific exercise classes. Regular activity helps manage weight, improves insulin sensitivity, reduces gestational diabetes risk, and supports overall wellbeing. Women should discuss appropriate exercise with their midwife or obstetrician.
There are no specific medications approved for treating NAFLD during pregnancy. Agents sometimes used outside pregnancy, such as vitamin E or pioglitazone, are not recommended during pregnancy due to lack of safety data. Weight-loss medications should be avoided. Management therefore relies on lifestyle interventions and treatment of associated conditions. Women should review all medications with their maternity team to ensure safety in pregnancy.
When to Seek Medical Advice
Women with fatty liver disease should maintain regular contact with healthcare professionals throughout pregnancy, but certain symptoms require urgent medical attention. Severe or persistent abdominal pain, particularly in the upper right quadrant where the liver is located, warrants immediate assessment. Whilst some abdominal discomfort is normal in pregnancy, severe or unusual pain could indicate complications requiring prompt evaluation. Women should contact their maternity assessment or triage unit for advice, or attend the emergency department if the unit is not immediately accessible.
Jaundice – yellowing of the skin or whites of the eyes – is never normal during pregnancy and requires immediate medical review. Associated symptoms including dark urine (tea-coloured), pale or clay-coloured stools, and severe itching (particularly affecting palms and soles) may indicate intrahepatic cholestasis of pregnancy or other liver complications. These symptoms should prompt urgent contact with maternity services or attendance at an emergency department, as cholestasis requires monitoring and may necessitate earlier delivery.
Persistent nausea and vomiting beyond the first trimester, or severe vomiting at any stage that prevents adequate nutrition and hydration, requires medical assessment. Whilst morning sickness is common in early pregnancy, severe symptoms later in pregnancy could indicate conditions such as acute fatty liver of pregnancy or pre-eclampsia. Women should also seek advice if they experience severe headaches, visual disturbances (such as flashing lights or blurred vision), or sudden swelling of face, hands, or feet, as these may indicate pre-eclampsia, which requires urgent assessment and management.
Any unusual bleeding or reduced foetal movements should prompt immediate contact with maternity services, as these may indicate foetal compromise. Women should be familiar with their baby's normal movement patterns from around 24 weeks gestation and report any concerns promptly. The RCOG advises that if a woman notices her baby moving less than usual, she should contact her midwife or maternity unit straight away. Additionally, symptoms of infection including fever, chills, or burning during urination require medical review, as infections can be more serious during pregnancy.
For life-threatening emergencies such as severe bleeding, seizures, collapse, or difficulty breathing, women should call 999 immediately.
For non-urgent concerns, women should contact their midwife, GP, or obstetrician through normal channels. This includes questions about diet, exercise, medication safety, or general pregnancy symptoms. Most maternity units provide telephone triage services for pregnancy-related concerns. Women should never hesitate to seek advice if worried, as healthcare professionals would rather assess and reassure than miss important complications. Early identification and management of problems significantly improves outcomes for both mother and baby, making open communication with healthcare teams essential throughout pregnancy.
After pregnancy, women with NAFLD should have follow-up to review their liver health, support weight management if appropriate, and assess cardiovascular and diabetes risk. This may involve review with the GP or, if indicated, ongoing hepatology follow-up. Maintaining a healthy lifestyle, including balanced diet and regular physical activity, remains important for long-term liver and metabolic health.
Frequently Asked Questions
Can I have a healthy pregnancy if I have fatty liver disease?
Yes, most women with uncomplicated fatty liver disease can have healthy pregnancies with appropriate medical supervision. The key is understanding your specific liver condition—simple steatosis without significant inflammation or scarring typically does not prevent pregnancy, whilst advanced fibrosis or cirrhosis requires specialist assessment and careful planning before conception.
Does having fatty liver increase my risk of complications during pregnancy?
Women with fatty liver disease have modestly increased risks of gestational diabetes and pre-eclampsia, though these are often related to associated metabolic conditions such as obesity and insulin resistance rather than the liver disease itself. With regular monitoring and appropriate management of risk factors, most women have successful pregnancies without major complications.
What tests should I have before trying to conceive with fatty liver?
Before conception, you should have liver function tests, fibrosis assessment using scores such as FIB-4 or NAFLD fibrosis score, and possibly an Enhanced Liver Fibrosis (ELF) blood test or liver ultrasound. Your healthcare team will also review associated conditions, optimise medications for pregnancy safety, and recommend folic acid supplementation and lifestyle modifications to improve liver and metabolic health.
Is fatty liver disease the same as acute fatty liver of pregnancy?
No, pre-existing fatty liver disease and acute fatty liver of pregnancy (AFLP) are completely different conditions. Pre-existing fatty liver is a chronic metabolic condition present before pregnancy, whilst AFLP is a rare obstetric emergency that develops in the third trimester with different causes and requires immediate delivery of the baby.
What lifestyle changes can help manage fatty liver during pregnancy?
Focus on a balanced diet rich in whole foods, fruits, vegetables, whole grains, and lean proteins whilst limiting processed foods and refined sugars, and aim for at least 150 minutes of moderate-intensity physical activity weekly, such as brisk walking or swimming. Pregnancy is not the time for weight loss, but maintaining appropriate gestational weight gain and healthy habits supports both liver health and foetal development.
When should I contact my doctor during pregnancy if I have fatty liver?
Seek urgent medical attention if you experience jaundice (yellowing of skin or eyes), severe abdominal pain, persistent vomiting beyond the first trimester, severe itching (especially on palms and soles), severe headaches, visual disturbances, or sudden swelling of face or hands. These symptoms may indicate serious complications such as intrahepatic cholestasis of pregnancy or pre-eclampsia that require immediate assessment and management.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
